Optimal provision of daytime NPH insulin in patients using the insulin analog lispro

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro and NPH Insulin (isophane).

As an approach to resolving this problem, the researchers performed a randomized, crossover study with four treatment arms, comparing the daytime metabolic profile after either premeal lispro alone or premeal lispro with optimal daytime NPH insulin and with standard human regular insulin.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

On each study day, patients received one of the four study insulin treatments, in random order, with identical meals and snacks.

All patients were using their usual premeal plus basal insulin regimen during the period of the study, with human regular insulin before meals and NPH insulin at bedtime.

How the Study Was Run

The design is described as randomized and crossover.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Blood Glucose, C-Peptide, Circadian Rhythm, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Lispro and NPH Insulin (isophane).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page and the NPH Insulin (isophane) compound page, all human trials.